Valuation : Grace Therapeutics, Inc.

Market Cap 62.3M 45.19M 38.88M 36.49M 33.38M 4.27B 62.8M 432M 168M 2.18B 170M 166M 7.03B P/E 2027 *
-1.78x
P/E 2028 * -4.63x
Enterprise Value 62.3M 45.19M 38.88M 36.49M 33.38M 4.27B 62.8M 432M 168M 2.18B 170M 166M 7.03B EV / Sales 2027 *
-
EV / Sales 2028 * 9.11x
Free-Float
81.8%
Yield 2027 *
-
Yield 2028 * -
1 day+1.17%
1 week+1.39%
Current month+2.82%
1 month+5.29%
3 months-10.61%
6 months-44.27%
Current year-36.71%
1 week 2.07
Extreme 2.07
2.2
1 month 2.02
Extreme 2.02
2.25
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.72
Extreme 1.72
5.18
5 years 1.72
Extreme 1.72
14.88
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 03/04/2023
Director of Finance/CFO 55 04/01/2024
Chief Tech/Sci/R&D Officer 65 07/05/2023
Director TitleAgeSince
Chairman 57 -
Director/Board Member 54 03/04/2023
Director/Board Member 59 09/10/2023
Date Insider Type Main position Quantity % Market Cap. Importance
28/08/26 Free

Executive/Senior Manager

35,760 0.2197%
28/08/26 Free

Chief Technology Officer

54,690 0.3361%
28/08/26 Free

Chief Executive Officer

267,160 1.6416%
Change 5-day change 1-year change 3-year change Capi.($)
+1.17%+1.39%-26.26%+4.78% 45.02M
+1.03%-2.05%+39.28%+94.60% 68.87B
+1.31%+0.55%+49.48%+92.12% 65.29B
-0.96%+3.32%-12.60%+375.60% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-0.53%-7.41%+2.71%-15.45% 26.08B
+1.01%+1.38%+26.48%-17.50% 20.14B
+3.45%-14.83%+225.22%+389.50% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+1.70%+7.43%+60.62%+166.57% 14.5B
Average +1.19%-2.44%+40.64%+165.45% 28.04B
Weighted average by Cap. +1.10%-2.12%+42.71%+142.11%

Financials

2027 *2028 *
Net sales - 6.84M 4.96M 4.27M 4.01M 3.67M 469M 6.9M 47.39M 18.46M 240M 18.63M 18.23M 772M
Net income -34.73M -25.19M -21.67M -20.34M -18.61M -2.38B -35M -241M -93.69M -1.22B -94.59M -92.52M -3.92B -16.92M -12.27M -10.56M -9.91M -9.06M -1.16B -17.05M -117M -45.64M -593M -46.07M -45.07M -1.91B
Net Debt - -
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
03/09/26 US$2.190 +2.34% 125,226
02/09/26 US$2.140 +1.90% 48,982
01/09/26 US$2.100 -1.41% 78,967
31/08/26 US$2.130 +0.47% 117,306
28/08/26 US$2.120 -1.85% 66,108
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.962CAD
Average target price
8.342CAD
Spread / Average Target
+181.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock